NCT03495323View on ClinicalTrials.gov

A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

May 16, 2018

Primary Completion Date

February 1, 2021

Study Completion Date

February 1, 2021

Conditions
Cancer
Interventions
DRUG

LY3300054

LY3300054 is a monoclonal antibody that targets programmed cell death ligand 1 (

DRUG

Prexasertib

Prexasertib work by preventing the cancer cells from being able to repair damaged DNA (one of the building blocks of a cell) which then leads to cell death

Trial Locations (1)

02215

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT03495323 - A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter